Radiopharm Theranostics and TerraPower announced an agreement that will help advance the next generation of radiopharmaceutical therapies for cancer treatment. Since 2018, TerraPower has been working to increase the supply of Actinium-225 from Thorium-229 decay, which is derived from Uranium-233 managed by the U.S. Department of Energy. Actinium-225 is an alpha-emitting radionuclide with significant promise in effectively treating cancer patients.

It can be attached to a targeting molecule, which will then selectively target and destroy cancerous tissue. Under this agreement, TerraPower's subsidiary, TerraPower Isotopes, LLC, will supply Actinium-225 to Radiopharm Theranostics. The Actinium-225 will be utilized in drug trials involving targeted alpha therapy in multiple disease areas.